<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are disorders characterized by a profound impairment of proliferation and maturation of hematopoietic cells </plain></SENT>
<SENT sid="1" pm="."><plain>The prognosis is poor owing to the occurrence of severe cytopenia or to the common leukemic transformation of these conditions </plain></SENT>
<SENT sid="2" pm="."><plain>At present there is no available effective treatment for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>A patient is reported with simple <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> which responded to therapy with high doses of maturative factors (<z:chebi fb="9" ids="27470">folic acid</z:chebi> and <z:chebi fb="9" ids="17439">vitamin B12</z:chebi>) </plain></SENT>
<SENT sid="4" pm="."><plain>This therapy resulted in the disappearance of transfusion requirements and in the increase of peripheral blood cell counts </plain></SENT>
<SENT sid="5" pm="."><plain>It is concluded that, in view of the lack of toxicity of the treatment with madurative factors, this therapy should be attempted in a sequential fashion in <z:hpo ids='HP_0000001'>all</z:hpo> patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e> </plain></SENT>
</text></document>